LOX

Across TCGA pan-cancer cohorts, LOX mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LOX’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LOX mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LOX is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where LOX tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LOX mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	IV	+2.272	<.001	12	view →
HNSC	All	IV	+0.920	<.001	8	view →
COAD	Female	All	−0.345	.010	5	view →
PDAC	All	All	+0.290	<.001	4	view →
LUAD	Male	All	+0.215	.003	2	view →
LSCC	All	All	+0.137	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LOX–CCRCC

Open the CCRCC breakdown →